الأربعاء 10 جمادى الأولى 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
تحقق من أن الموقع يستخدم بروتوكول HTTPS
مسجل لدى هيئة الحكومة الرقمية برقم :
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease | Bayer | Terminated | Finerenone | 3 | BAY 94-8862 16244 | King Abdulaziz University Hospital (Jeddah) |
| "A randomized, double-blind Phase III study of copanlisib versusplacebo in patients with rituximab-refractory indolent non-Hodgkin’slymphoma (iNHL) – CHRONOS-2" | Bayer | Terminated | BAY 80-6946/Copanlisib | 3 | BAY 80-6946 / 17322 | King Abdulaziz University Hospital (Jeddah), King Abdullah Medical City (Makkah), King Fahad Specialist Hospital (Dammam) |
| Single arm Phase I/II study of the safety, tolerability and efficacy of the investigational anti PD-L1 monoclonal antibody Durvalumab in combination with Paclitaxel in patients with metastatic triple negative PD-L1 positive breast cancer | AstraZeneca | Ongoing | MEDI4736/Paclitaxel | 2 | ESR-14-10649 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) | AstraZeneca | Ongoing | MEDI4736+Tremelimumab | 3 | D419AC00003 | King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Randomized, three- way, three- period, single oral dose, open-label, crossover, bioequivalence study to compare Lorvast Tablets /Tabuk Pharmaceutical Mfg. Co. (20 mg Atorvastatin), versus Lipitor® (20 mg Atorvastatin) Produced by Pfizer in healthy subjects under fasting conditions. | SFDA | Completed | Lipitor® lovarst tablet | 4 | 42370 | saudi Ajal |
| RIFTOS MKI - Radioactive Iodine reFractory asymptomatic patients in differentiated Thyroid cancer – an Observational Study to assess the use of MultiKinase Inhibitors | Bayer | Ongoing | Nexavar (Sorafenib) | 4 | 17852 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Treatment Patterns, Outcomes, and Resource Use Study For Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-Squamous)in Kingdom of Saudi Arabia and United Arab Emirates | Bristol-Myers Squibb | Ongoing | - | 4 | CA209454 | King Abdulaziz Medical City NG (Riyadh) |
| SAUDI ARABIA – A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Roche | Ongoing | N/A | 4 | ML29618 | King Abdulaziz Medical City NG (Riyadh) |
| The study of efficacy and saftey of Rituximab in treatment of resistant glomerulonephritis | The Saudi center for Organ Transplantation (SCOT) | Ongoing | Rituximab | 3 | MN-101-11 | King Fahad Medical City (Riyadh), King Abdulaziz Hospital and Oncology Center (Jeddah), Dammam Medical Complex, King Fahad Hospital (Jeddah), Armed Forces Hospital (Al-Hada), Armed Forces Hospital (Southern Region), King Fahad University Hospital (Al-Khobar), King Fahd Armed Forces Hospital (Jeddah) |
| Phase III, Double-Blind, Placebo-Controlled Study Of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With Or Without Nimotuzumab For Stage III/IV Head And Neck Squamous Cell Cancer | King Fahad Medical City | Ongoing | Nimotuzumab | 3 | 1HN01 | King Fahad Medical City (Riyadh) |
تاريخ آخر تحديث: 06/10/2026 بتمام الساعة 08:14 صباحا بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.